Enhabit, Inc. (NYSE:EHAB) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Enhabit, Inc. (NYSE:EHAB) have been given a consensus recommendation of “Reduce” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $12.08.

A number of research firms have recently commented on EHAB. UBS Group raised Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 target price on the stock in a research note on Thursday, March 7th. Jefferies Financial Group reduced their target price on Enhabit from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, March 6th. Finally, Oppenheimer reissued a “market perform” rating on shares of Enhabit in a research note on Thursday, March 7th.

Enhabit Stock Down 0.8 %

NYSE EHAB opened at $10.16 on Thursday. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.76. Enhabit has a 52 week low of $7.12 and a 52 week high of $14.59. The firm has a market capitalization of $509.58 million, a price-to-earnings ratio of -6.27, a PEG ratio of 1.60 and a beta of 1.96. The company has a fifty day moving average of $10.15 and a two-hundred day moving average of $9.86.

Enhabit (NYSE:EHAB) last released its earnings results on Wednesday, March 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01. The firm had revenue of $260.60 million during the quarter, compared to analyst estimates of $260.30 million. Enhabit had a negative net margin of 7.69% and a positive return on equity of 1.55%. During the same quarter last year, the business earned $0.32 EPS. On average, analysts predict that Enhabit will post 0.24 earnings per share for the current year.

Institutional Trading of Enhabit

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp acquired a new position in Enhabit during the 2nd quarter valued at about $494,000. Millennium Management LLC purchased a new position in shares of Enhabit in the second quarter worth $230,000. UBS Group AG lifted its stake in shares of Enhabit by 407,300.0% during the third quarter. UBS Group AG now owns 12,222 shares of the company’s stock worth $171,000 after buying an additional 12,219 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Enhabit during the third quarter valued at $9,662,000. Finally, Credit Suisse AG acquired a new position in shares of Enhabit in the 3rd quarter valued at $686,000.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.